Current opinion in cardiology · 2009
Percutaneous mitral valve therapy: when? Which patients?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mack Michael
Аннотация
PURPOSE OF REVIEW: Transcatheter management of valvular heart disease is an emerging area of intense interest. Patients with mitral regurgitation present a large clinical unmet need for therapeutic advances.
RECENT FINDINGS: A large randomized, pivotal trial of one device, which performs an edge-to-edge repair, has recently completed enrollment and is awaiting all patients to reach the primary clinical endpoint. A host of other devices are still in preclinical or early clinical feasibility trials after having undergone device iteration. Clinical trials with two devices have been stopped because of disappointing early results.
SUMMARY: Although the field of transcatheter treatment of aortic stenosis is proceeding at a brisk pace with commercial approval of two devices in Europe, percutaneous treatment of mitral regurgitation has progressed at a much more measured pace because of varying cause of the disease, complexity of valvular anatomy, imaging, and delivery issues.
RECENT FINDINGS: A large randomized, pivotal trial of one device, which performs an edge-to-edge repair, has recently completed enrollment and is awaiting all patients to reach the primary clinical endpoint. A host of other devices are still in preclinical or early clinical feasibility trials after having undergone device iteration. Clinical trials with two devices have been stopped because of disappointing early results.
SUMMARY: Although the field of transcatheter treatment of aortic stenosis is proceeding at a brisk pace with commercial approval of two devices in Europe, percutaneous treatment of mitral regurgitation has progressed at a much more measured pace because of varying cause of the disease, complexity of valvular anatomy, imaging, and delivery issues.